Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B3UE
|
||||
| Former ID |
DNC008818
|
||||
| Drug Name |
9-Cyclopentyl-9H-adenine
|
||||
| Synonyms |
9-Cyclopentyl-9H-purin-6-ylamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H13N5
|
||||
| Canonical SMILES |
C1CCC(C1)N2C=NC3=C2N=CN=C3N
|
||||
| InChI |
1S/C10H13N5/c11-9-8-10(13-5-12-9)15(6-14-8)7-3-1-2-4-7/h5-7H,1-4H2,(H2,11,12,13)
|
||||
| InChIKey |
KTJWHJNBTXITCB-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [2] | |
| Adenosine A2a receptor | Target Info | Inhibitor | [2] | ||
| Adenosine A1 receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| Monoamine Transport | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 1991 Sep;34(9):2877-82.N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. | ||||
| REF 2 | Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. Epub 2009 Feb 23.8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.